Eptifibatide in peripheral vascular interventions: Results of the Integrilin Reduces Inflammation in Peripheral Vascular Interventions (INFLAME) trial

Journal of Invasive Cardiology

Volumn 18, Issue 1, 2006, Pages 6-12

  Shammas, Nicolas W ^a   Dippel, Eric J ^a   Lemke, Jon H ^a   Robken, Jon ^a   Kirchner, Lester ^a   Takes, Vickie ^a   Kapalis, Matthew J ^a   Palabrica, Theresa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INTERLEUKIN 6; THROMBIN;

ANTICOAGULANT THERAPY; ARTERY; ARTERY DILATATION; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TIME; CARDIOVASCULAR INFLAMMATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; HUMAN; HYPOTHESIS; ILIAC ARTERY; INFRAINGUINAL ARTERY; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LOW DRUG DOSE; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR INTERVENTION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME;

AGED; ANEURYSM, FALSE; ANTICOAGULANTS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOGEN; HEMORRHAGE; HEPARIN; HUMANS; INFLAMMATION; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PEPTIDES; PERIPHERAL VASCULAR DISEASES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBIN; TIME FACTORS; WHOLE BLOOD COAGULATION TIME;

EID: 33645889344     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998;98:2370-2376.
2. Schillinger M, Exner M, Mlekusch W, et al. Inflammatory response to stent implantation: Differences in femoropopliteal, iliac and carotid arteries. Radiology 2002;224:529-535.
3. Azar RR, Badaoui G, Sarkis A, et al. Effects of tirofiban and statins on high-sensitivity Creactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease. Am J Cardiol 2005;95:236-240.
4. Merino A, Gaya A, Segura I, et al. Platelet aggregation inhibition blocks C-reactive protein and interleukin-6 (IL-6) elevation after the coronary angioplasty: Effect of the -174 G/C IL-6 gene polymorphism. Am J Cardiol 2004;94:1300-1303.
5. Akbulut M, Ozbay Y, Gundogdu O, et al. Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions. Curr Med Res Opin 2004;20:1759-1767.
6. Li JJ, Fang CH, Jiang H, et al. Time course of inflammatory response after renal artery stenting in patients with atherosclerotic renal stenosis. Clin Chim Acta 2004;350:115-121.
7. Welt FGP, Rogers SD, Zhang X, et al. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter Cardiovasc Interv 2004;61:185-189.
8. Cipollone F, Ferri C, Desideri G, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003;108:2776-2782.
9. Aggarwal A., Schneider DJ, Terrien EF, et al. Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardiol 2003;91;1346-1349.
10. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-167.
11. Aggarwal A, Blum A, Schneider DJ, et al. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coron Artery Dis 2004;15:471-475.
12. Inoue T, Hoshi K, Yaguchi I, et al. Serum levels of circulating adhesion molecules after coronary angioplasty. Cardiology 1999;91:236-242.
13. Kereiakes DJ. Inflammation as a therapeutic target: A unique role for abciximab. Am Heart J 2003;146(Suppl 4):S1-4.
14. Donal E, Nanadoumgar H, Ragot S, et al. Value of systematic dosage of biological markers of inflammation for the prognosis at 12 months of patients undergoing programmed coronary angioplasty. Arch Mal Coeur Vaiss 2005;98:101-107.
15. Hojo Y, Ikeda U, Katsuki T, et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000;84:83-87.
16. Hoshida S, Nishino M, Takeda T, et al. A persistent increase in Creactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. Atherosclerosis 2004;173:285-290.
17. Schillinger M, Exner M, Mlekusch W, et al. Endovascular revascularization below the knee: 6-month results and predictive value of C-reactive protein level. Radiology 2003;227:419-425.
18. Mlekusch W, Exner M, Schillinger M, et al. E-Selectin and restenosis after femoropopliteal angioplasty: Prognostic impact of the Ser128Arg genotype and plasma levels. Thromb Haemost 2004;91:171-179.
19. Inoue T, Sakai Y, Morooka S, et al. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996;28:1127-1133.
20. Lee WL, Sheu WH, Liu TJ, et al. The short-/intermediate-term changes in novel vascular inflammatory markers after angioplasty plus stenting in patients with symptomatic advanced systemic arterial diseases. Atherosclerosis 2004;176:125-132.
21. Schillinger M, Exner M, Mlekusch W, et al. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: Association with restenosis. Radiology 2002;225:21-26.
22. Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: Predictive role of C-reactive protein. Circulation 2002;105:800-803.
23. Shammas NW, Dippel EJ. Inflammation and cardiovascular risk: An overview. Int J Angiol 2004;13:161-167.
24. Dormandy J, Heeck L, Vig S. The natural history of claudication: Risk to life and limb. Semin Vasc Surg 1999;12:123-127.
25. Tschopl M, Tsakiris DA, Marbet GA, et al. Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol 1997;17:3208-3214.
26. Shammas NW. Complications in peripheral vascular interventions: Emerging role of direct thrombin inhibitors. J Vasc Interv Radiol 2005;16:165-171
27. Schillinger M, Exner M, Mlekusch W, et al. Balloon angioplasty and stent implantation induce a vascular inflammatory reaction. J Endovasc Ther 2002;9:59-66.
28. Ercan E, Tengiz I, Duman C, et al. Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction. Am Heart J 2004;147:E1.
29. Akbulut M, Ozbay Y, Gundogdu O, et al. Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions. Curr Med Res Opin 2004;20:1759-1767.
30. Bonz AW, Lengenfelder B, Jacobs M, et al. Cytokine response after percutaneous coronary intervention in stable angina: Effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J 2003;145:693-699.
31. Shammas NW, Lemke JH, Dippel EJ, et al. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. J Invasive Cardiol 2003;15:242-246.
32. Freedman JE, Loscalzo J. Platelet-monocyte aggregates. Bridging thrombosis and inflammation. Circulation 2002;105:2130-2132.
33. Furman MI, Frelinger Al 3rd, Michelson AD. Gp IIb/IIIa inhibitor-induced dethrombosis. J Thromb Thrombolysis 2004;18:11-17.
34. Steiner S, Seidinger D, Huber K, et al. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Arterioscler Thromb Vasc Biol 2003;23:1697-1702
35. Neumann FJ, Zohlnhofer D, Fakhoury L, et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999;34:1420-1426.
36. Keating FK, Dauerman HL, Whitaker DA, et al. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis 2005;16:401-405.
37. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res 2000;45:437-446.
38. Gawaz M, Ruf A, Pogatsa-Murray G, et al. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: Importance of internal pool of glycoprotein IIb-IIIa receptors. Thromb Haemost 2000;83:915-922.
39. Tsao PW, Forsythe MS, Mousa SA. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb Res 1997;88:137-146.
40. Matzdorff AC, Kuhnel G, Kemkes-Matthes B, et al. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro. J Lab Clin Med 2000;135:247-255.
41. Klinkhardt U, Kirchmaier CM, Westrup D, et al. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abciximab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters. Thromb Res 2000;97:201-207.
42. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial. Lancet 2000;356:2037-2044.